Tue, Feb 13, 2024
The Street estimates Ipca Labs' EBITDA to soar by 60 per cent to Rs 345 crore in the quarter under review from Rs 216 crore in the same quarter last fiscal. The pharma firm's margins, meanwhile, are estimated to rise to 16 per cent in the December quarter from 14 per cent in the third quarter last year.
More >
Mon, Oct 23, 2023
IPCA Laboratories' share price surged 7% to hit a 52-week high on Oct 23 after the company received a voluntary action indicated (VAI) classification for its Ratlam plant from the US FDA. What's a VAI classification and why is it good news for IPCA Laboratories?
Mon, Jun 26, 2023
The American regulatory authority has issued 11 objections to the API plant of Ratlam, Madhya Pradesh, on June 14.
Tue, May 30, 2023
IPCA Laboratories share price NSE: Shares of Ipca Laboratories edged lower on May 30, Tuesday, a day after the pharmaceutical company based in Mumbai reported its Q4 earnings.
Thu, Nov 25, 2021
Lyka Labs shares touched a new 52-week high value of Rs 142.35 on back of share acquisition by Ipca Laboratories in the company.
Fri, Mar 19, 2021
IPCA Laboratories formulations segment revenues are set to grow strongly over the next two years, backed by a double digit growth in the domestic formulations. Over the past two months of January and February 2021, the company has consistently outperformed the IPM (Indian Pharmaceutical Markets) growth substantially attributable to the strong presence in the gastro – intestinal and pain segments.
Wed, Dec 16, 2020
CLSA highlights that it was a muted month for pharma companies as November sales disappoint for the Domestic Market. CLSA says it was a strong month for IPCA Labs; gains from integration of acquired brands for Dr Reddy. Falling active cases meant sales of Covid treatment drugs moderated for Glenmark / Cipla (+16%/-24% MoM). Glenmark saw the highest growth in its coverage in November, but excluding these products, its portfolio fell 1% YoY. Cipla’s core growth was a smaller 5.9% YoY.
Fri, Nov 06, 2020
CGSCIMB says they believe the domestic business’s strong recovery in growth should ensure healthy cash flows and better RocE. They initiate coverage on the Pharma sector with Overweight rating; add rating on Dr Reddy’s Labs, Cadila Healthcare, Alkem Labs, Cipla, IPCA Labs, Natco Pharma, Ajanta Pharma, Indoco Remedies and Hold rating on Alembic Pharma, Torrent Pharma.
Thu, Nov 05, 2020
Market expert Simi Bhowmick, while talking to Zee Business Managing Editor Anil Singhvi on the Special Mid-cap Picks show was as bullish as the wider markets and recommended IPCA Labs, Balaji Amines and Tata Elxsi as her long-term, positional and short-term picks.
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
